Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. Dr. Sherman is responsible for Harvard Pilgrim’s medical trend management, provider engagement strategy, medical informatics, wellness and health promotion initiatives, care and disease management services, pharmacy services, NCQA accreditation, and quality and utilization management programs, and he has been a leader in driving adoption of outcomes-based provider and pharmaceutical contracts. He also serves on the faculty of Harvard Medical School’s Department of Population Medicine, as Chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). Dr. Sherman also is the current Chair for AHIP’s CMO Leadership Council, comprised of chief medical officers from health plans throughout the United States.
Prior to joining Harvard Pilgrim, Dr. Sherman held leadership roles at Humana, UnitedHealth Group, and Thomson Medstat (now IBM Truven). He holds a BA and an MS in Biomedical Anthropology from the University of Pennsylvania and received his MD from Yale and MBA from the Harvard Business School. Dr. Sherman is a diplomate of the American Board of Anesthesiology and American Board of Medical Management, and he practiced as a cardiac anesthesiologist prior to pursuing his MBA. A fellow of the American College of Physician Executives, Dr. Sherman was also appointed by then Governor Deval Patrick to represent the health plan perspective on the Massachusetts Statewide Quality Advisory Committee.
Dr. Sherman is a frequent speaker at national and regional conferences and has lectured as part of the Harvard Business School executive education program on value measurement in health care. He currently serves on the board of directors and as Co-president of the Harvard Business School Healthcare Alumni Association, as well as on the board of advisors for the Harvard Business School Healthcare Initiative, the board of directors for the Personalized Medicine Coalition, and the board of overseers for Boston’s internationally renowned Museum of Science.
How outcomes-based payment agreements between payer and pharma could help resolve issues of drug access and affordability.